Susceptibility of human T-cell leukemia virus type I-infected cells to humanized anti-CD30 monoclonal antibodies in vitro and in vivo

Naoyoshi Maeda, Hiromi Muta, Ezogelin Oflazoglu, Yasunobu Yoshikai

    Research output: Contribution to journalArticle

    14 Citations (Scopus)

    Abstract

    Adult T-cell leukemia (ATL) is an aggressive malignancy of activated CD4 + T cells associated with human T-cell leukemia virus type I (HTLV-I) infection. No conventional chemotherapy regimen has appeared successful in patients with ATL, thus establishing effective therapy is urgently required. In some cases, ATL tumor cells express CD30 on the cell surface, therefore, a therapy with mAb against CD30 would be beneficial. To investigate the effect of CD30-mediated therapy on ATL, we assessed SGN-30, a chimeric anti-CD30 mAb, and SGN-35, a monomethyl auristatin E-conjugated anti-CD30 mAb, in vitro and in vivo. Three HTLV-I-infected cell lines were co-cultured with SGN-30 or SGN-35, and the growth-inhibitory effects on the HTLV-I-infected cells were evaluated using an in vitro cell proliferation assay and cell cycle analysis. SGN-30 and SGN-35 showed growth-inhibitory activity against the HTLV-I-infected cell lines by apoptosis and/or cell growth arrest in vitro. To further investigate the effects of SGN-30 and SGN-35 on HTLV-I-infected cells in vivo, we used NOD/SCID mice subcutaneously engrafted with HTLV-I-infected cells. Both mAbs significantly inhibited the growth of HTLV-I-infected cell tumors in the NOD/SCID murine xenograft models. These data suggest that CD30-mediated therapy with SGN-30 or SGN-35 would be useful for patients with ATL.

    Original languageEnglish
    Pages (from-to)224-230
    Number of pages7
    JournalCancer Science
    Volume101
    Issue number1
    DOIs
    Publication statusPublished - Jan 1 2010

    Fingerprint

    Human T-lymphotropic virus 1
    Adult T Cell Leukemia Lymphoma
    Monoclonal Antibodies
    Growth
    Cell Line
    Neoplasms
    Inbred NOD Mouse
    SCID Mice
    Virus Diseases
    Therapeutics
    In Vitro Techniques
    Heterografts
    Cell Cycle
    Cell Proliferation
    cAC10-vcMMAE
    Apoptosis
    T-Lymphocytes
    Drug Therapy

    All Science Journal Classification (ASJC) codes

    • Oncology
    • Cancer Research

    Cite this

    Susceptibility of human T-cell leukemia virus type I-infected cells to humanized anti-CD30 monoclonal antibodies in vitro and in vivo. / Maeda, Naoyoshi; Muta, Hiromi; Oflazoglu, Ezogelin; Yoshikai, Yasunobu.

    In: Cancer Science, Vol. 101, No. 1, 01.01.2010, p. 224-230.

    Research output: Contribution to journalArticle

    Maeda, Naoyoshi ; Muta, Hiromi ; Oflazoglu, Ezogelin ; Yoshikai, Yasunobu. / Susceptibility of human T-cell leukemia virus type I-infected cells to humanized anti-CD30 monoclonal antibodies in vitro and in vivo. In: Cancer Science. 2010 ; Vol. 101, No. 1. pp. 224-230.
    @article{03beb32ec11548ff8e376ffce7bd7050,
    title = "Susceptibility of human T-cell leukemia virus type I-infected cells to humanized anti-CD30 monoclonal antibodies in vitro and in vivo",
    abstract = "Adult T-cell leukemia (ATL) is an aggressive malignancy of activated CD4 + T cells associated with human T-cell leukemia virus type I (HTLV-I) infection. No conventional chemotherapy regimen has appeared successful in patients with ATL, thus establishing effective therapy is urgently required. In some cases, ATL tumor cells express CD30 on the cell surface, therefore, a therapy with mAb against CD30 would be beneficial. To investigate the effect of CD30-mediated therapy on ATL, we assessed SGN-30, a chimeric anti-CD30 mAb, and SGN-35, a monomethyl auristatin E-conjugated anti-CD30 mAb, in vitro and in vivo. Three HTLV-I-infected cell lines were co-cultured with SGN-30 or SGN-35, and the growth-inhibitory effects on the HTLV-I-infected cells were evaluated using an in vitro cell proliferation assay and cell cycle analysis. SGN-30 and SGN-35 showed growth-inhibitory activity against the HTLV-I-infected cell lines by apoptosis and/or cell growth arrest in vitro. To further investigate the effects of SGN-30 and SGN-35 on HTLV-I-infected cells in vivo, we used NOD/SCID mice subcutaneously engrafted with HTLV-I-infected cells. Both mAbs significantly inhibited the growth of HTLV-I-infected cell tumors in the NOD/SCID murine xenograft models. These data suggest that CD30-mediated therapy with SGN-30 or SGN-35 would be useful for patients with ATL.",
    author = "Naoyoshi Maeda and Hiromi Muta and Ezogelin Oflazoglu and Yasunobu Yoshikai",
    year = "2010",
    month = "1",
    day = "1",
    doi = "10.1111/j.1349-7006.2009.01354.x",
    language = "English",
    volume = "101",
    pages = "224--230",
    journal = "Cancer Science",
    issn = "1347-9032",
    publisher = "Wiley-Blackwell",
    number = "1",

    }

    TY - JOUR

    T1 - Susceptibility of human T-cell leukemia virus type I-infected cells to humanized anti-CD30 monoclonal antibodies in vitro and in vivo

    AU - Maeda, Naoyoshi

    AU - Muta, Hiromi

    AU - Oflazoglu, Ezogelin

    AU - Yoshikai, Yasunobu

    PY - 2010/1/1

    Y1 - 2010/1/1

    N2 - Adult T-cell leukemia (ATL) is an aggressive malignancy of activated CD4 + T cells associated with human T-cell leukemia virus type I (HTLV-I) infection. No conventional chemotherapy regimen has appeared successful in patients with ATL, thus establishing effective therapy is urgently required. In some cases, ATL tumor cells express CD30 on the cell surface, therefore, a therapy with mAb against CD30 would be beneficial. To investigate the effect of CD30-mediated therapy on ATL, we assessed SGN-30, a chimeric anti-CD30 mAb, and SGN-35, a monomethyl auristatin E-conjugated anti-CD30 mAb, in vitro and in vivo. Three HTLV-I-infected cell lines were co-cultured with SGN-30 or SGN-35, and the growth-inhibitory effects on the HTLV-I-infected cells were evaluated using an in vitro cell proliferation assay and cell cycle analysis. SGN-30 and SGN-35 showed growth-inhibitory activity against the HTLV-I-infected cell lines by apoptosis and/or cell growth arrest in vitro. To further investigate the effects of SGN-30 and SGN-35 on HTLV-I-infected cells in vivo, we used NOD/SCID mice subcutaneously engrafted with HTLV-I-infected cells. Both mAbs significantly inhibited the growth of HTLV-I-infected cell tumors in the NOD/SCID murine xenograft models. These data suggest that CD30-mediated therapy with SGN-30 or SGN-35 would be useful for patients with ATL.

    AB - Adult T-cell leukemia (ATL) is an aggressive malignancy of activated CD4 + T cells associated with human T-cell leukemia virus type I (HTLV-I) infection. No conventional chemotherapy regimen has appeared successful in patients with ATL, thus establishing effective therapy is urgently required. In some cases, ATL tumor cells express CD30 on the cell surface, therefore, a therapy with mAb against CD30 would be beneficial. To investigate the effect of CD30-mediated therapy on ATL, we assessed SGN-30, a chimeric anti-CD30 mAb, and SGN-35, a monomethyl auristatin E-conjugated anti-CD30 mAb, in vitro and in vivo. Three HTLV-I-infected cell lines were co-cultured with SGN-30 or SGN-35, and the growth-inhibitory effects on the HTLV-I-infected cells were evaluated using an in vitro cell proliferation assay and cell cycle analysis. SGN-30 and SGN-35 showed growth-inhibitory activity against the HTLV-I-infected cell lines by apoptosis and/or cell growth arrest in vitro. To further investigate the effects of SGN-30 and SGN-35 on HTLV-I-infected cells in vivo, we used NOD/SCID mice subcutaneously engrafted with HTLV-I-infected cells. Both mAbs significantly inhibited the growth of HTLV-I-infected cell tumors in the NOD/SCID murine xenograft models. These data suggest that CD30-mediated therapy with SGN-30 or SGN-35 would be useful for patients with ATL.

    UR - http://www.scopus.com/inward/record.url?scp=71849105156&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=71849105156&partnerID=8YFLogxK

    U2 - 10.1111/j.1349-7006.2009.01354.x

    DO - 10.1111/j.1349-7006.2009.01354.x

    M3 - Article

    C2 - 19799612

    AN - SCOPUS:71849105156

    VL - 101

    SP - 224

    EP - 230

    JO - Cancer Science

    JF - Cancer Science

    SN - 1347-9032

    IS - 1

    ER -